Journal of Clinical Oncology
Articles in this Issue
Trastuzumab deruxtecan (T-DXd) in patients (pts) with <i>HER2</i> -mutant (HER2m) non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases (mets): Results from DESTINY-Lung05 (DL-05).
e20500 Background: T-DXd (5.4 mg/kg) is approved in multiple countries for pretreated unresectable/metastatic HER2...
Patient preferences for duration of adjuvant trastuzumab for HER2+ breast cancer.
e12518 Background: A recent meta-analysis of reduced duration adjuvant trastuzumab trials demonstrated that 6 months was n...
A phase II study of the DNA plasmid-based vaccine STEMVAC in patients with metastatic triple-negative breast cancer (mTNBC).
TPS2698 Background: Adding immune checkpoint inhibitors for the treatment of mTNBC improves the efficacy of traditional ch...
Comparing line of therapy selection methods in advanced non–small cell lung cancer (aNSCLC): A simulation study.
e23357 Background: External control arms utilizing real-world patients are increasingly used with single-arm clinical tria...
Effects of malnutrition on in-hospital outcomes among young adults hospitalized with gastrointestinal cancers: A multicentric retrospective cohort study.
e16490 Background: Protein–energy malnutrition (PEM) is common in gastrointestinal (GI) cancers and may worsen inpatient o...
Longitudinal assessment of circulating tumor DNA as a disease monitoring biomarker in soft tissue sarcoma.
e23523 Background: Soft tissue sarcomas (STS) comprise a heterogeneous group of malignancies with limited biomarkers for r...
Survival outcomes following resistance to immune checkpoint inhibition in advanced cutaneous squamous cell carcinoma.
9588 Background: Immune checkpoint inhibitors (ICI) are standard first-line therapy for advanced cutaneous squamous cell c...
Beyond detection: Five-year screening behaviors and patient-reported perceptions in DETECT-A participants.
10534 Background: Multi-cancer early detection (MCED) blood testing may improve early cancer detection. The impact of MCED...
A single-arm, phase II study of sequential therapy with curative intent in de novo HER2+ metastatic breast cancer: The SAPPHO study.
TPS1147 Background: Due to dramatic improvements in neoadjuvant and adjuvant HER2-directed therapy (tx), most patients (pt...
Determinants of lung metastasis in pediatric and young adult differentiated thyroid cancer: A meta-analytic study.
e18107 Background: Distant metastases from differentiated thyroid cancer (DTC) occur more frequently in children and young...
A Korea–USA multicenter study of duodenal pancreatic fluid–derived exosomal CES1 and MAN2A1 as pancreas-proximal biomarkers for early pancreatic cancer detection.
10552 Background: Small pancreatic lesions often yield limited tissue via endoscopic ultrasound (EUS)-guided biopsy, and s...
Improving availability and quality of serious illness documentation using large language models.
e13693 Background: Timely access to prior documented serious illness conversations (SICs) is critical for inpatient clinic...
Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced <i>EGFR</i> -mutant NSCLC in the US and China.
e23169 Background: The FLAURA2 and MARIPOSA trials established overall survival benefits of osimertinib plus chemotherapy...
Frequency of mutations in homologous recombination genes in patients with different histological types of gastric cancer.
e16031 Background: Gastric cancer (GC) is the leading cause of cancer-related death worldwide. Despite advances in treatme...
A randomized controlled trial evaluating anamorelin hydrochloride in patients with gastric cancer cachexia (TEAM-GUSTO).
e16037 Background: Cancer cachexia is a multifactorial metabolic syndrome associated with treatment interruption, deterior...
Patterns and timing of palliative care consultation in patients with newly diagnosed metastatic cancer.
12064 Background: Early integration of palliative care (PC) improves symptom burden, quality of life, and healthcare utili...
Surgical de-escalation in high-risk resectable melanoma with major pathologic response (MPR) after neoadjuvant immune checkpoint inhibition (ICI).
9574 Background: Neoadjuvant ICI renders MPR in 50-60% of resectable Stage III/IV melanoma. Early data illustrated the abi...
BL0020, a novel tumor microenvironment (TME)-targeting nano-mediated polypeptide-drug conjugate (NMPDC), in patients with advanced solid tumors: Updated results from the small cell lung cancer (SCLC) subset of a phase 1 study.
8095 Background: BL0020 is a novel polypeptide-drug nanoconjugate (~10 nm in size) composed of PEG-modified poly(amino aci...
Clinical factors driving use of RET inhibitor pralsetinib and associated real-world outcomes in <i>RET</i> fusion–positive NSCLC: A retrospective chart review.
e20731 Background: Selective RET (REarranged during Transfection) inhibitors (RETi) have become standard treatment for...
Real-world outcomes and immune and cardiopulmonary toxicities of durvalumab following concurrent chemoradiotherapy in non–small cell lung cancer.
e20097 Background: Durvalumab consolidation following concurrent chemoradiotherapy (CCRT) has improved overall survival (O...
Subtype-specific melatonin receptor expression on circulating tumor cells and associated inflammatory/metabolic biomarkers in breast cancer: A 3-year cohort analysis (n=171).
e13016 Background: Melatonin signaling modulates inflammation, extracellular matrix remodeling, and tumor metabolism. We i...
Real-world costs of care and discontinuation among patients receiving adjuvant CDK4/6 inhibitors in early breast cancer.
e12517 Background: For patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2...
The significance of MDM-2 positivity in stage 4 non-small cell lung cancer.
e20599 Background: MDM-2 positivity is discussed as a potential indicator of resistance to immunotherapy and targeted ther...
Prophylactic tocilizumab to mitigate cytokine release syndrome in patients receiving tarlatamab: A single-center exploratory experience informed by bispecific antibody safety data.
8082 Background: Tarlatamab, a bispecific T-cell engager (BiTE) targeting CD3 on T cells and DLL3 on small cell lung cance...
Cerebrospinal fluid cell-free tumor DNA-based cancer molecular profiling vs. cytology examination: A comparison in cancer detection sensitivity.
e15057 Background: The evaluation tools with the central nervous system (CNS) tumors includes magnetic resonance imaging (...